BDBM259408 US10457647, Example 7::US11180460, Example 7::US11673868, Example 7::US9512084, 7

SMILES C\C=C\C(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2F)C2CC2)c1C

InChI Key InChIKey=MAEVSXHQLPMRFL-SNAWJCMRSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 259408   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  42nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  42nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  104nMAssay Description:Inhibition of full-length human recombinant BTK using FITC-Ahx-TSELKKVVALYDYMPMNAND-NH2 as substrate measured after 60 mins by caliper assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  42nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  983nMAssay Description:Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  42nMAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM259408(US10457647, Example 7 | US11180460, Example 7 | US...)
Affinity DataIC50:  263nMAssay Description:Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HT...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed